Insmed ranks No. 90 on the Deloitte Technology Fast 500 List, North America.
2022
Insmed holds its inaugural Global Day of Good, a company-wide day of service to support the communities where employees live and work.
2022
Insmed announces strategic financings that will enable the Company to deliver clinical data from each of its four pillars.
2023
Insmed completes enrollment of adult patients in its Phase 3 ASPEN study.
2023
Insmed announces positive topline results from its Phase 3 ARISE study.
2023
Insmed is re-certified as a Great Place to Work in the U.S. and ranks No. 1 on Science magazine’s Top Biopharma Employers List for the third year in a row.